"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremias · Water Intoxication
Phase 3
Completed
205
2026-07
Industry sponsor intelligence
Otsuka Pharmaceutical Development & Commercialization, Inc.Clinical Pipeline.
Lead-sponsor view of Otsuka Pharmaceutical Development & Commercialization, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 0
- Avg enrollment
- 224
Pipeline overview
Programs by phase and activity.
Velocity
Otsuka Pharmaceutical Development & Commercialization, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 10
Phase 20
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Vasopressin → | 2 | 0 | 0 | 2 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Study of Ascending Levels of Tolvaptan in Hyponatremia
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremia
Phase 3
Completed
243
2026-07
Search sponsor records
All Otsuka Pharmaceutical Development & Commercialization, Inc. studies.
This page groups studies where Otsuka Pharmaceutical Development & Commercialization, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first